Regioisomerization Strategy in Iridium(III) Complexes Achieving Enhanced Type I Photosensitization and Tumor Photoimmunotherapy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Feng Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China. Hauptthemen laut MEDLINE: Iridium, Photosensitizing Agents, Photochemotherapy, Coordination Complexes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Science and Technology Foundation of Shenzhen City, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
While molecular isomers exhibit nearly identical compositions, their spatial arrangement often dictates distinct physicochemical properties. We present a regioisomer engineering strategy to construct two iridium(III) complexes (Ir1 and Ir2) through precise positioning of triphenylamine electron donors relative to the metal chelation core. Compared to Ir1, Ir2 features strategically displaced donors that create a contracted bandgap, reduced oxidation potential, and amplified spin-orbit coupling (SOC). These electronic modifications synergistically enable Ir2 to achieve superior type I photodynamic activity and thus generate O2•- and •OH radicals after 633 nm irradiation even under hypoxic conditions. The sustained reactive oxygen species (ROS) production induces potent immunogenic cell death (ICD), ultimately stimulating dendritic cell maturation and antitumor immunity. This regioisomeric design paradigm establishes a molecular blueprint for oxygen-tolerant photosensitizers, addressing the critical challenge of hypoxia in photoimmunotherapy applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China.
- Department of Medical Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China.
- Department of Materials Chemistry, Huzhou University, Huzhou 313000, China.
- School of Pharmaceutical Science (Shenzhen), Shenzhen campus of Sun Yat-sen University, Shenzhen 518107, China.
ORCID-Profile: Huaiyi Huang, Pingyu Zhang
Förderung
- Science and Technology Foundation of Shenzhen City
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Shenzhen Medical Research Fund
Zitieren
APA
Chen, F., Ma, H., Wen, G., Wu, X., Lin, X., Li, D., Wang, D., Dao, A., Huang, H., & Zhang, P. (2025). Regioisomerization Strategy in Iridium(III) Complexes Achieving Enhanced Type I Photosensitization and Tumor Photoimmunotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01006
Vancouver
Chen F, Ma H, Wen G, Wu X, Lin X, Li D, et al. Regioisomerization Strategy in Iridium(III) Complexes Achieving Enhanced Type I Photosensitization and Tumor Photoimmunotherapy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01006
BibTeX
@article{Chen2025,
author = {Chen, Feng and Ma, Hongbiao and Wen, Guoqing and Wu, Xuan and Lin, Xintong and Li, Dan and Wang, Deliang and Dao, Anyi and Huang, Huaiyi and Zhang, Pingyu},
title = {Regioisomerization Strategy in Iridium(III) Complexes Achieving Enhanced Type I Photosensitization and Tumor Photoimmunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01006}
}
EUVIMED